These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 3333881)

  • 21. The pharmocogenomics of warfarin: closing in on personalized medicine.
    Rettie AE; Tai G
    Mol Interv; 2006 Aug; 6(4):223-7. PubMed ID: 16960144
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Inhibition by warfarin of liver microsomal vitamin K-reductase in warfarin-resistant and susceptible rats.
    MacNicoll AD; Nadian AK; Townsend MG
    Biochem Pharmacol; 1984 Apr; 33(8):1331-6. PubMed ID: 6712738
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hydroxylation of warfarin by human cDNA-expressed cytochrome P-450: a role for P-4502C9 in the etiology of (S)-warfarin-drug interactions.
    Rettie AE; Korzekwa KR; Kunze KL; Lawrence RF; Eddy AC; Aoyama T; Gelboin HV; Gonzalez FJ; Trager WF
    Chem Res Toxicol; 1992; 5(1):54-9. PubMed ID: 1581537
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Warfarin pharmacology, clinical management, and evaluation of hemorrhagic risk for the elderly.
    Jacobs LG
    Cardiol Clin; 2008 May; 26(2):157-67, v. PubMed ID: 18406992
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hepatic microsomal warfarin metabolism in warfarin-resistant and susceptible mouse strains: influence of pretreatment with cytochrome P-450 inducers.
    Sutcliffe FA; MacNicoll AD; Gibson GG
    Chem Biol Interact; 1990; 75(2):171-84. PubMed ID: 2369784
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Vitamin K-dependent carboxylation and vitamin K metabolism in liver. Effects of warfarin.
    Wallin R; Martin LF
    J Clin Invest; 1985 Nov; 76(5):1879-84. PubMed ID: 3932474
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2.
    Rost S; Fregin A; Ivaskevicius V; Conzelmann E; Hörtnagel K; Pelz HJ; Lappegard K; Seifried E; Scharrer I; Tuddenham EG; Müller CR; Strom TM; Oldenburg J
    Nature; 2004 Feb; 427(6974):537-41. PubMed ID: 14765194
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Normal and warfarin-resistant rat hepatocyte metabolism of vitamin K 2,3-epoxide: evidence for multiple pathways of hydroxyvitamin K formation.
    Trivedi LS; Rhee M; Galivan JH; Fasco MJ
    Arch Biochem Biophys; 1988 Jul; 264(1):67-73. PubMed ID: 3395132
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Norfloxacin does not alter warfarin's disposition or anticoagulant effect.
    Rocci ML; Vlasses PH; Distlerath LM; Gregg MH; Wheeler SC; Zing W; Bjornsson TD
    J Clin Pharmacol; 1990 Aug; 30(8):728-32. PubMed ID: 2401751
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Biochemical basis of warfarin and bromadiolone resistance in the house mouse, Mus musculus domesticus.
    Misenheimer TM; Lund M; Baker EM; Suttie JW
    Biochem Pharmacol; 1994 Feb; 47(4):673-8. PubMed ID: 8129744
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacogenetics of oral anticoagulants.
    Daly AK; King BP
    Pharmacogenetics; 2003 May; 13(5):247-52. PubMed ID: 12724615
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mechanism for potentiation of warfarin by phenylbutazone. Inhibition of vitamin K-dependent carboxylation and prothrombin synthesis by phenylbutazone in preparations from rat liver.
    Kelly LJ; Bell RG
    Biochem Pharmacol; 1981 Sep; 30(17):2443-9. PubMed ID: 21043243
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Oral anticoagulant drugs: pharmacokinetic aspects.
    Breckenridge A
    Semin Hematol; 1978 Jan; 15(1):19-26. PubMed ID: 341326
    [No Abstract]   [Full Text] [Related]  

  • 34. Is personalized medicine a dream or a reality?
    Morse BL; Kim RB
    Crit Rev Clin Lab Sci; 2015 Feb; 52(1):1-11. PubMed ID: 25181036
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Novel revelation of warfarin resistant mechanism in roof rats (Rattus rattus) using pharmacokinetic/pharmacodynamic analysis.
    Takeda K; Ikenaka Y; Tanikawa T; Tanaka KD; Nakayama SM; Mizukawa H; Ishizuka M
    Pestic Biochem Physiol; 2016 Nov; 134():1-7. PubMed ID: 27914534
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Vitamin K requirement in Danish anticoagulant-resistant Norway rats (Rattus norvegicus).
    Markussen MD; Heiberg AC; Nielsen R; Leirs H
    Pest Manag Sci; 2003 Aug; 59(8):913-20. PubMed ID: 12916772
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The relationship between the vitamin K cycle inhibition and the plasma anticoagulant response at steady-state S-warfarin conditions in the rat.
    Mosterd JJ; Thijssen HH
    J Pharmacol Exp Ther; 1992 Mar; 260(3):1081-5. PubMed ID: 1545379
    [TBL] [Abstract][Full Text] [Related]  

  • 38. VKORC1: a warfarin-sensitive enzyme in vitamin K metabolism and biosynthesis of vitamin K-dependent blood coagulation factors.
    Wallin R; Wajih N; Hutson SM
    Vitam Horm; 2008; 78():227-46. PubMed ID: 18374197
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Warfarin-induced changes in procoagulant and anticoagulant proteins.
    Stirling Y
    Blood Coagul Fibrinolysis; 1995 Jul; 6(5):361-73. PubMed ID: 8589201
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Effect of Shuxuetong injection on anticoagulant effect of warfarin in rats].
    Zhao HF; Sun JH; Liu S; Liu Y; Liu GF
    Zhongguo Zhong Yao Za Zhi; 2017 Mar; 42(5):982-988. PubMed ID: 28994544
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.